In the last trading session, 0.86 million Mereo Biopharma Group Plc ADR (NASDAQ:MREO) shares changed hands as the company’s beta touched 0.41. With the company’s per share price at $2.29 changed hands at $0.05 or 2.23% during last session, the market valuation stood at $364.11M. MREO’s last price was a discount, traded about -119.21% off its 52-week high of $5.02. The share price had its 52-week low at $1.58, which suggests the last value was 31.0% up since then.
Analysts gave the Mereo Biopharma Group Plc ADR (MREO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.11. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended MREO as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
Instantly MREO was in green as seen at the end of in last trading. With action -8.40%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -34.57%, with the 5-day performance at -8.40% in the red. However, in the 30-day time frame, Mereo Biopharma Group Plc ADR (NASDAQ:MREO) is -0.43% down.
The consensus price target for the stock as assigned by Wall Street analysts is 7.5, meaning bulls need an upside of 69.47% from its current market value. According to analyst projections, MREO’s forecast low is 4 with 8 as the target high. To hit the forecast high, the stock’s price needs a -249.34% plunge from its current level, while the stock would need to soar -74.67% for it to hit the projected low.
Mereo Biopharma Group Plc ADR (MREO) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 34.82%. The 2025 estimates are for Mereo Biopharma Group Plc ADR earnings to increase by 40.48%, but the outlook for the next 5-year period is at 20.63% per year.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 1.6566% or 11.79 million shares worth $42.45 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund and Tema ETF Trust-Tema GLP-1, Obesity & Cardiometabolic ETF. With 759.1 shares estimated at $1.74 million under it, the former controlled 0.48% of total outstanding shares. On the other hand, Tema ETF Trust-Tema GLP-1, Obesity & Cardiometabolic ETF held about 0.17% of the shares, roughly 267.46 shares worth around $0.61 million.
